Pulmonary arterial hypertension

Inclusion Criteria

-  Male or female subjects aged ≥18 years
 -  Newly Treated with Ventavis or treated with Ventavis for less than 6 months, with I Neb AAD device for the application, as described in the SmPC (Summary of Product Characteristics), complemented by the Insight
 -  With Pulmonary Arterial Hypertension, Group I of the Dana point Pulmonary Hypertension Classification.
 -  WHO (World Health Organization) /NYHA (New York Heart Association) Functional class III
 -  Able and willing to give written informed consent for participation in the study

Exclusion Criteria

Key contra indications:
 -  Hypersensitivity to the active substance or to any of the excipients. 
 -  Conditions where the effects of Ventavis on platelets might increase the risk of haemorrhage (e.g. active peptic ulcers, trauma, intracranial haemorrhage). 
 -  Severe coronary heart disease or unstable angina; 
 -  Myocardial infarction within the last six months; 
 -  Decompensated cardiac failure if not under close medical supervision; 
 -  Severe arrhythmias; 
 -  Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months. 
 -  Pulmonary hypertension due to venous occlusive disease. 
 -  Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension